Health Economics & Outcomes Research
Cytel’s experts in Health Economics & Outcomes Research generate evidence-based cost-effectiveness models that showcase the true economic value of your product. They specialize in health economic modeling, HEOR value communication, and other standard models of pharmaceutical modeling for comparative effectiveness research.
Intelligence
Delivery of advanced insights using methods like Bayesian network meta-analysis, indirect treatment comparisons, comprehensive literature reviews, decision-analysis models for complex health interventions, and more.
Confidence
Evidence-generation, knowledge-synthesis and value communication for industry-leading real world evidence solutions.
Cytel HEOR Publications
Cost-Effectiveness Analyses
Cost-Consequence Models
Budget Impact Models
ITC / NMA / STC / MAIC
QOL / Utility
Real World Evidence
Systematic Literature Review
Early Economic Models & Value Frameworks
Health Economic Methods
Endpoint Validation
Health Technology Assessments
- Cost-Effectiveness Of Tesamorelin In The Treatment Of Lipohypertrophy In The US. Azimpour K, Tremblay G, de Chantal M, Marsolais C. Value in Health (2020).
- Economic Evaluation of Eribulin as Second-Line Treatment for Metastatic Breast Cancer in South Korea. Tremblay, G., U. Majethia, J. L. Breeze, I. Kontoudis, and J. Park. ClinicoEconomics and Outcomes Research : CEOR 8 (September 2016): 485–93. https://doi.org/10.2147/CEOR.S110553.
- Cost-Effectiveness Analysis of a HMGA2 Prognostic Test for Acute Myeloid Leukemia in a Canadian Setting. Tremblay, G., B. Rousseau, M. Marquis, C. Beaubois, G. Sauvageau, and J. Hebert. Applied Health Economics and Health Policy 17, no. 6 (December 2019): 827–39. https://doi.org/10.1007/s40258-019-00503-5.
- Cost-Effectiveness Analysis for Midostaurin versus Standard of Care in Acute Myeloid Leukemia in the United Kingdom. Tremblay, G., M. Dolph, S. Patel, P. Brandt, and A. Forsythe. Cost Effectiveness and Resource Allocation: C/E 16 (2018): 33. https://doi.org/10.1186/s12962-018-0153-4.
- Cost-Effectiveness Analysis of Midostaurin (MIDO) with Standard Chemotherapy (SOC) for Acute Myeloid Leukemia (AML) in the United Kingdom (UK). Tremblay, G., M. Dolph, S. Patel, P. Brandt, and A. Forsythe. Oral presentation presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Glasgow, Scotland, November 4, 2017.
- Cost-Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in France. Tremblay, G., C. Cariou, C. Recher, M. Dolph, P. Brandt, A.-S. Blanc, and A. Forsythe. The European Journal of Health Economics, January 22, 2020. https://doi.org/10.1007/s10198-019-01149-9.
- Cost-Effectiveness Model of Midostaurin (MIDO) Versus Standard of Care (SOC) In Patients With Newly Diagnosed FLT3 Mutation-Positive (FLT3+) Acute Myeloid Leukemia (AML): A French Perspective. Cariou, C., G. Tremblay, M. Dolph, P. S. Brandt, and A. Forsythe. Oral presentation presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Barcelona, Spain, November 10, 2018.
- Cost-Effectiveness Analysis of Midostaurin (MIDO) With Standard of Care (SOC) for Acute Myeloid Leukemia (AML) in Canada. Tremblay, G., M. Dolph, K. El Ouagari, P. Brandt, and A. Forsythe. Baltimore, MD, USA, 2018. https://doi.org/10.1016/j.jval.2018.04.180.
- The Cost-Effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States. Tremblay G, Dolph M, Nidumolu Roy A, Said Q, Forsythe A. Clinical Therapeutics, 2020. ISSN 0149-2918. https://doi.org/10.1016/j.clinthera.2020.02.020.
- A Canadian Cost-Effectiveness Analysis for the Treatment of Immune Thrombocytopenia: Assessing the Relative Value of with Eltrombopag Versus Romiplostim. Tremblay, G., M. Dolph, A. Roy, J. Neyra, K. El Ouagari, and A. Forsythe. Atlanta, GA, USA, 2017. https://ashpublications.org/blood/article/130/Supplement 1/3410/114517/A-Canadian-Cost-Effectiveness-Analysis-for-the.
- Cost-Effectiveness Analysis of Ofatumumab As a Treatment for Relapsed Chronic Lymphocytic Leukemia in the United States. Tremblay, G., A. Forsythe, V. Bal, S. Santra, and A. Briggs. San Diego, CA, 2016. https://doi.org/10.1182/blood.V128.22.2366.2366.
- Cost-Effectiveness Model Comparing Expanded Umbilical Cord Blood Transplants With Other HSCT Strategies For Patients With Haematological Malignancies. Tremblay, G., M. Dolph, G. Sauvageau, and S. Cohen. New Orleans, LA, USA, 2019. https://doi.org/10.1016/j.jval.2019.04.173.
- Cost-Effectiveness Model Comparing Suba-Itraconazole (SUBA-ITRA) Versus Conventional Itraconazole (ITRA) For Treating Systemic Mycoses In The U.S. Tremblay, G., T. Westley, M. Dolph, D. Newman, and G. Lewis. New Orleans, LA, USA, 2019. https://doi.org/10.1016/j.jval.2019.04.170.
- Cost-Effectiveness Model Comparing Therapeutic Strategies For Treating Iron Deficiency Anaemia (IDA) In Inflammatory Bowel Disease (IBD). Tremblay, G., M. Dolph, T. Jones, A. Forsythe, L. Mellor, and M. Sampson. Barcelona, Spain, 2018. https://doi.org/10.1016/j.jval.2018.09.2669.
- Cost-Effectiveness Model Comparing the Novel Subcutaneous Antipsychotic RBP-7000 to Intramuscular Paliperidone Palmitate to Treat Patients with Acutely Exacerbated Schizophrenia. Forsythe, A., G. Tremblay, M. Dolph, R. Dhanda, J. Patterson, V. Nadipelli, N. Rashid, L. Citrome, and C. U. Correll. Orlando, FL, 2018. https://www.jmcp.org/doi/10.18553/jmcp.2018.24.10-a.s1.
- Cost-Effectiveness of Dolutegravir as a First-Line Treatment Option in the HIV-1-Infected Treatment-Naive Patients in Russia. Tremblay, G., V. Chounta, J. Piercy, T. Holbrook, S. A. Garib, E. K. Bukin, and Y.S. Punekar. Value in Health Regional Issues 16 (September 2018): 74–80. https://doi.org/10.1016/j.vhri.2018.08.001.
- Improving Access to Antiretrovirals in China: Economic Analyses of Dolutegravir in HIV-1 Patients. Punekar, Y.S., N. Guo, G. Tremblay, J. Piercy, T. Holbrook, and B. Young. Cost Effectiveness and Resource Allocation : C/E 17 (2019): 26. https://doi.org/10.1186/s12962-019-0195-2.
- Cost-Effectiveness of Perampanel for the Treatment of Primary Generalized Tonic-Clonic Seizures (PGTCS) in Epilepsy: A Spanish Perspective. Tremblay, G., D. Howard, W. Tsong, V. Patel, and J. De Rosendo. Epilepsy & Behavio : E&B 86 (September 2018): 108–15. https://doi.org/10.1016/j.yebeh.2018.06.002.
- Cost-Consequence Model Comparing Eltrombopag and Romiplostim in Pediatric Patients with Chronic Immune Thrombocytopenia. Tremblay, G., M. Dolph, M. Bhor, Q. Said, A. Roy, B. Elliott, and A. Briggs. ClinicoEconomics and Outcomes Research : CEOR 10 (2018): 715–21. https://doi.org/10.2147/CEOR.S177338.
- Cost-Consequence Model Comparing Eltrombopag versus Romiplostim for Adult Patients with Chronic Immune Thrombocytopenia. Tremblay, G., M. Dolph, M. Bhor, Q. Said, B. Elliott, and A. Briggs. ClinicoEconomics and Outcomes Research : CEOR 10 (2018): 705–13.
- Comparing Costs and Consequences of Eltrombopag Plus IST Versus IST Alone for First-Line Treatment in Severe Aplastic Anemia: Results from a Responder Analysis, Tremblay, G., Q. Said, B. Cai, S. A. Garib, D. Tomaras, A. Forsythe, and A. Roy. 132:1041–1041. San Diego, CA, 2018. https://doi.org/10.1182/blood-2018-99-115138.
- Cost-Consequence Model Comparing Eltrombopag and Romiplostim for Pediatric Patients with Previously-Treated Chronic Immune Thrombocytopenia. Tremblay, G., M. Bhor, A. Roy, B. Elliott, M. Dolph, A. Forsythe, and A. Briggs. Atlanta, GA, USA, 2017. https://ashpublications.org/blood/article/130/Supplement 1/2146/71530
- Clinical Validation Of A Budget Impact Model Using The Established Key Opinion Leader Validation Framework (KOLVF). Tremblay G, Azimpour K. Value in Health (2020).
- Budget Impact Of Eltrombopag As First-Line Treatment For Severe Aplastic Anemia In The United States. Tremblay, G., Q. Said, A. N. Roy, B. Cai, S. A Garib, J. Hearnden, and A. Forsythe. ClinicoEconomics and Outcomes Research: CEOR 11 (2019): 673–81. https://doi.org/10.2147/CEOR.S226323.
- Budget Impact of Suba-Itraconazole Capsules (SUBA-ITRA) For The Treatment Of Systemic Mycoses In The U.S. Tremblay, G., T. Westley, M. Dolph, D. Newman, and G. Lewis. New Orleans, LA, USA, 2019. https://doi.org/10.1016/j.jval.2019.04.176.
- "The Budget Impact of Novel Subcutaneous Once-Monthly Long-Acting Injectable Antipsychotic (LAI) RBP-7000 (Risperidone in the Atrigel® Delivery System) in Patients with Acute Schizophrenia." Forsythe, A., S. A. Garib, G. Tremblay, R. Dhanda, J. Patterson, V. Nadipelli, N. Rashid, L. Citrome, and C. U. Correll. Orlando, FL, 2018. https://www.jmcp.org/doi/10.18553/jmcp.2018.24.10-a.s1.
- Budget Impact of Perampanel as Adjunctive Treatment of Uncontrolled Partial-Onset and Primary Generalized Tonic-Clonic Seizures in the United States. Tremblay, G., V. Barghout, V. Patel, W. Tsong, and Z. Wang. Epilepsy & Behavio : E&B 68 (March 2017): 196–202. https://doi.org/10.1016/j.yebeh.2016.12.029.
- US Budget Impact Model for Selinexor in Relapsed or Refractory Multiple Myeloma. Bassali, Jan, Ian Gopal Gould, James A. Kaye, Deirdre Mladsi, and Jyotsna Mehta. ClinicoEconomics and Outcomes Research. Dove Press, June 19, 2020. https://doi.org/10.2147/CEOR.S251070.
- Overall Survival of Glasdegib in Combination with Low-Dose Cytarabine, Azacitidine, and Decitabine among Adult Patients with Previously Untreated AML: Comparative Effectiveness Using Simulated Treatment Comparisons. Tremblay, G., T. Westley, J. C. Cappelleri, B. Arondekar, G. Chan, T. J. Bell, and A. Briggs. ClinicoEconomics and Outcomes Research : CEOR 11 (2019): 551–65. https://doi.org/10.2147/CEOR.S203482.
- Indirect Number Needed To Treat: Comparative Effectiveness Of Glasdegib + Low-Dose Cytarabine Vs Azacitidine Or Decitabine In Acute Myeloid Leukemia Patients Ineligible For Intensive Chemotherapy. Tremblay, G., T. Westley, S. A. Garib, T. Bell, J. C. Cappelleri, G. Chan, and A. Forsythe. Amsterdam, UK, 2019. http://journals.lww.com/10.1097/01.HS9.0000562476.96992.f3.
- Indirect Comparative Effectiveness of Treatments for Older Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (NIC): Combinations Glasdegib + Low-Dose Cytarabine (GLAS+LDAC) vs Decitabine or Venetoclax + LDAC. Tremblay, G., T. Westley, T. J. Bell, J. C. Cappelleri, G. Chan, J. Hearnden, and A. Forsythe. Glasgow, Scotland, 2019. https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.15854.
- Systematic Literature Review And Indirect Comparison of Glasdegib Plus Low Dose ARA-C Versus A Hypomethylating Agent For Acute Myeloid Leukemia Patients Ineligible For Intensive Chemotherapy. Forsythe, A., B. Arondekar, G. Tremblay, G. Chan, and Y. Su. Madrid, Spain, 2017. https://linkinghub.elsevier.com/retrieve/pii/S1098301517304370.
- Comparative Effectiveness of Combination Glasdegib+ Low-Dose Cytarabine (GLAS+LDAC) Vs Combination Venetoclax + Low-Dose Cytarabine (VEN+LDAC) Among Older Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (NIC): Indirect Treatment Comparison (ITC) Methods. Westley, T., A. Forsythe, T. J. Bell, J. C. Cappelleri, G. Chan, and G. Tremblay. San Diego, CA, 2018. https://ashpublications.org/blood/article/132/Supplement 1/1429/262867/Comparative-Effectiveness-of-Combination-Glasdegib.
- Clinical Responses of Glasdegibplus Low-Dose Ara-C, Azacitidine, and Decitabine Among Acute Myeloid Leukemia (AML) Patients Ineligible to Receive Intensive Chemotherapy: Comparative Effectiveness Using Indirect Treatment Comparison (ITC) Methods. Westley, T., A. Forsythe, T. J. Bell, J. C. Cappelleri, G. Tremblay, and G. Chan. San Diego, CA, 2018. https://ashpublications.org/blood/article/132/Supplement 1/2709/264110/Clinical-Responses-of-Glasdegibplus-Low-Dose-Ara-C.
- Covariate Adjusted Indirect Treatment Comparison (ITC) of Glasdegib Plus Low Dose Ara-C Versus a Hypomethylating Agent for Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy. Tremblay, G., B. Arondekar, G. Chan, A. Shor, A. Forsythe, and S. Yun. Blood 130, no. Supplement 1 (December 7, 2017): 5665–5665. https://doi.org/10.1182/blood.V130.Suppl_1.5665.5665.
- Systematic Literature Review And Indirect Comparison of Glasdegib Plus Low Dose ARA-C Versus A Hypomethylating Agent For Acute Myeloid Leukemia Patients Ineligible For Intensive Chemotherapy. Forsythe, A., B. Arondekar, G. Tremblay, G. Chan, and Y. Su. Glasgow, Scotland, 2017. https://doi.org/10.1016/j.jval.2017.08.103.
- A Systematic Literature Review and Network Meta-Analysis of Long-Acting Injectable Therapies (LAIs) for Acute Schizophrenia. Forsythe, A., M. Dolph, G. Tremblay, R. Dhanda, J. Patterson, V. Nadipelli, P. Pezalla, L. Citrome, and C. U. Correll. Orlando, FL, 2018. https://www.jmcp.org/doi/10.18553/jmcp.2018.24.10-a.s1.
- Evaluating Different Indirect Treatment Comparison Approaches: A Case Study in Acute Myeloid Leukemia Patients Ineligible to Receive Intensive Chemotherapy. Tremblay, G, T Westley, B Arondekar, J Cappelleri, G Chan, A Forsythe, and A Briggs. Baltimore, MD, USA, 2018. https://doi.org/10.1016/j.jval.2018.04.100.
- Matching-Adjusted Treatment Comparison (MAIC) of RBP-7000 Monthly Subcutaneous Injection and Paliperidone Palmitate Monthly Intramuscular Injection (PP1M) for Acute-Onset Schizophrenia. Forsythe, A., T. Westley, G. Tremblay, R. Dhanda, J. Patterson, V. Nadipelli, P. Pezalla, L. Citrome, and C. U. Correll. Orlando, FL, 2018. https://www.jmcp.org/doi/10.18553/jmcp.2018.24.10-a.s1.
- Matching-Adjusted Indirect Treatment Comparison of Ribociclib and Palbociclib in HR+, HER2- Advanced Breast Cancer. Tremblay, G., D. Chandiwana, M. Dolph, J. Hearnden, A. Forsythe, and M. Monaco. Cancer Management and Research 10 (2018): 1319–27. https://doi.org/10.2147/CMAR.S163478.
- Matching-Adjusted Indirect Treatment Comparison of Ribociclib and Palbociclib as First-Line Treatments for HR+, HER2– ABC. Forsythe, A., D. Chandiwana, M. Dolph, G. Tremblay, and M. Monaco. Madrid, Spain, 2017.
- Bayesian Network Meta-Analysis of Treatments in Iron Deficiency Anaemia (IDA). Tremblay, G, M Dolph, T Jones, and A Forsythe. Baltimore, MD, USA, 2018. https://linkinghub.elsevier.com/retrieve/pii/S1098301518319958.
- Using A Bayesian Network Meta-Analysis (NMA) To Compare Ferric Maltol To Treatments For Iron Deficiency And Iron Deficiency Anaemia Excluding CHF And CKD Patients. Jones, T., A. Forsythe, M. Sampson, G. Tremblay, and M. Dolph. Barcelona, Spain, 2018. https://doi.org/10.1016/j.jval.2018.09.2596.
- Number Needed to Treat in Indirect Treatment Comparison. Guyot, P., W. Cheng, G. Tremblay, R. Copher, H. Burnett, X. Li, and C. Makin. Journal of Comparative Effectiveness Research 7, no. 3 (March 2018): 259–69. https://doi.org/10.2217/cer-2017-0023.
- Network Meta-Analysis of Treatments For Unresectable Hepatocellular Carcinoma. Tremblay, G, G Meier, R Copher, D Misurski, J Pan, M Baig, T Tamai, S Kraljevic, A Shor, and A Forsythe. Glasgow, Scotland, 2017. https://doi.org/10.1016/j.jval.2017.08.096.
- Network Meta-Analysis (NMA) of Treatments for Unresectable Hepatocellular Carcinoma (UHCC). Tremblay, G., G. Meier, D. Misurski, M. Baig, T. Tamai, S. Kraljevic, A. Shor, and A. Forsythe. Madrid, Spain, 2017.
- Comparing ITC Results From Lenvatinib Plus Everolimus For Second-Line Treatment of Advanced/Metastatic Renal Cell Carcinoma: Crossover Versus No Crossover. Tremblay, G, SA Garib, G Meir, HJ McElroy, and M Guo. Glasgow, Scotland, 2017. https://doi.org/10.1016/j.jval.2017.08.106.
- Comparing ITC Results from Lenvatinib plus Everolimus for Second-Line Treatment of Advanced/Metastatic Renal Cell Carcinoma: Crossover versus No Crossover. Garib, S., G. Tremblay, G. Meier, H. McElroy, and M. Guo. Madrid, Spain, 2017.
- Matching-Adjusted Indirect Treatment Comparison in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer. Holbrook, T., G. Milligan, C. Pelletier, P. Rietschel, and G. Tremblay. Comparative Effectiveness Research, April 2016, 13. https://doi.org/10.2147/CER.S97885.
- Network Meta-analysis Comparing the Psychiatric Treatment-emergent Adverse Events of Eslicarbazepine Acetate and Brivaracetam. Mehra D et al. American Epilepsy Society Conference Proceedings (2020) – Accepted for publication at American Epilepsy Society Conference in 2020.
- Simulated Treatment Comparison (STC) of Human Mesenchymal Stromal Cells (Remestemcel-L, REM) and Ruxolitinib (RUX) for Steroid-Refractory Acute Graft-Versus-Host Disease (SR AGVHD) Pediatric Patients. Westley, T., D. Tomaras, E. Strati, D. Skerrett, A. Forsythe, and G. Tremblay. Orlando, FL, 2019. https://ashpublications.org/blood/article/134/Supplement_1/4545/424492/Simulated-Treatment-Comparison-STC-of-Human.
- Covariate Adjustment in Indirect Treatment Comparison (ITC): How To Blend The Useful With The Agreeable. Dolph, M., and G. Tremblay. Copenhagen, Denmark, 2019. https://doi.org/10.1016/j.jval.2019.09.1917.
- The use of simulated and indirect treatment comparison methods to evaluate therapies' comparative effectiveness: an interview with Gabriel Tremblay. Tremblay G,
- Comparative Effectiveness of Glasdegib or Venetoclax in Combination with Low-Dose Cytarabine Using Simulated Treatment Comparisons. Tremblay, G. Daniele, P. Dolph, P. et al.; Blood 2020; 136 (Supplement 1): 17–18. doi: https://doi.org/10.1182/blood-2020-137641
- Minimal Clinically Important Difference (MCID) For The Functional Assessment Of Cancer Therapy - Multiple Myeloma (FACT-MM): Two Approaches. Breeze J, Mehta J, Tremblay G. Value in Health (2020).
- Quality of Life (QOL) Analyses in Patients with Multiple Myeloma: Results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) Phase 2b Study. Jagannath, S., J. Mehta, J. Breeze, L. Lingling, N. Biran, S. Shacham, M. G. Kauffman, J. J. Shah. ASCO (American Society of Clinical Oncology) Journal Proceedings, (2020).
- Quality Of Life Analyses In Patients With Multiple Myeloma: Results From The Selinexor (KPT-330) Treatment Of Refractory Myeloma (STORM) Phase 2B Study. Breeze J, Mehta J, Tremblay G, Shacham S, Shah J, Jagannath S. Value in Health (2020).
- Health Utility in Relapsed/Refractory Dixuse Large B-Cell Lymphoma (RR-DLBCL) Patients - Results of a
Phase II Trial with ORAL Selinexor. Casasnovas RO , Daniele P , Tremblay G et al. Value in Health (2020) – Accepted for poster presentation at ISPOR EU 2020. - Systematic Literature Review (SLR) Of Health State Utility Values (HSUV) In Epidermal Growth Factor Receptor Mutant (Egfr-Mutant) Non-Small Cell Lung Cancer (NSCLC) Patients Previously Treated With Targeted Therapies. Shor, A, A Forsythe, S Li, and A Galaznik. Baltimore, MD, USA, 2018. https://doi.org/10.1016/j.jval.2018.04.300.
- Systematic Review Of Health State Utility Values For Economic Evaluation Of Acute Myeloid Leukemia. Forsythe, A., V. BaI, M. Dolph, S. Patel, and G. Tremblay. Madrid, Spain, 2017. https://library.ehaweb.org/eha/2017/22nd/180721/anna.forsythe.systematic.review.of.health.state.utility.values.for.economic.html?f=menu%3D14%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Aspeaker%3D619413.
- Health-Related Quality of Life in Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy: Results of a Systematic Literature Review. Forsythe, A., C. S. Kwon, T. Bell, T. A. Smith, and B. Arondekar. ClinicoEconomics and Outcomes Researc : CEOR 11 (2019): 87–98. https://doi.org/10.2147/CEOR.S187409.
- Health Related Quality Of Life (HRQOL) In Acute Myeloid Leukemia (AML) Patients Not Eligible For Intensive Chemotherapy (NIC AML): Results Of A Systematic Literature Review. Forsythe, A., C. S. Kwon, T. Bell, T. A. Smith, B. Arondekar, and A. P. J. Rabe. HemaSphere 2, no. S1 (June 14, 2018): 790–91.
- Systematic Review of Health State Utility Values for Acute Myeloid Leukemia. Forsythe, A., P. S. Brandt, M. Dolph, S. Patel, A. P. J. Rabe, and G. Tremblay. ClinicoEconomics and Outcomes Researc : CEOR 10 (2018): 83–92. https://doi.org/10.2147/CEOR.S153286.
- Mapping AcroQoL Scores to EQ-5D to Obtain Utility Values for Patients with Acromegaly. Badia, X., P. Trainer, N. R. Biermasz, J. Tiemensma, A. Carreno, M. Roset, A. Forsythe, and S. M. Webb. Journal of Medical Economics 21, no. 4 (April 2018): 382–89. https://doi.org/10.1080/13696998.2017.1419960.
- Mapping Acroqol Scores to EQ-5D to Obtain Utility Values for Patients with Acromegaly. Badia, X., N. Biermasz, J. Tiemensma, A. Carreno, M. Roset, and A. Forsythe. Glasgow, Scotland, 2017. https://doi.org/10.1016/j.jval.2017.08.484.
- Comparing Short Form – 6 Dimension (SF-6D) Derived Utilities and Euroqol Questionnaire – 5 Dimensions (EQ-5D) Mapped Utilities Among Patients with Iron Deficiency in Inflammatory Bowel Disease (ID-IBD) Treated with Ferric Maltol (FM) Vs Placebo. Tremblay, G, A Forsythe, A Rabe, and T Jones. Baltimore, MD, USA, 2018. https://doi.org/10.1016/j.jval.2018.04.585.
- Treatment with Ferric Maltol Associated with Improvements in Quality of Life for IBD Patients with Iron Deficiency Anaemia. Schmidt, C., D. Baumgart, B. Bokemeyer, C. Büning, S. Howaldt, A. Stallmach, C. Singfield, G. Tremblay, and T. Jones. Vienna, Austria, 2018. https://academic.oup.com/ecco-jcc/article/12/supplement_1/S346/4807586.
- Evaluation of Quality of Life at Progression in Patients with Soft Tissue Sarcoma. Hudgens, S., A. Forsythe, I. Kontoudis, D. D'Adamo, A. Bird, and H. Gelderblom. Sarcoma 2017 (2017): 2372135. https://doi.org/10.1155/2017/2372135.
- Quality of Life (QoL) in Pediatric Patients Treated with Remestemcel-L for Steroid-Refractory Acute Graft Versus Host Disease (AGVHD) Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): Analysis of Msb-GVHD001 Phase 3 Study. Strati, E., A. Forsythe, and G. Tremblay. Orlando, FL, 2020.
- The Use Of EQ-5D Visual Analog Scale (EQ-VAS) In Diseases Areas Where EQ-5D Is Insensitive To Changes In The Disease Status: The Case Of Lipodystrophy. Tremblay, G., M. de Chantal, A. Forsythe, and C. Marsolais. Copenhagen, Denmark, 2019. https://doi.org/10.1016/j.jval.2019.09.2632.
- A Framework For Conducting Probabilistic Sensitivity Analysis (PSA) When Modeling With Real-World Evidence (RWE) - How Good Is The Guidance? Ramjee L, Tremblay G. Value in Health (2020).
- Is There A Need For Real World Evidence (RWE) In Health Technology Assessments Of Rare Diseases And Oncology Treatments? Forsythe, A., D. Tomaras, F.J. Badia, O. Pirk, P. Rowe, J. F. Bergman, A. Walker, F. U. Fricke, and G. Tremblay. Copenhagen, Denmark, 2019. https://doi.org/10.1016/j.jval.2019.09.2184.
- Real World Evidence (RWE) In Partition Survival Modelling: Is It The Real Deal? Ramjee, L., G. Tremblay, and A. Forsythe. Copenhagen, Denmark, 2019. https://doi.org/10.1016/j.jval.2019.09.1923.
- Using Real World Evidence for Decision-Making In Health Technology Assessment: Case Studies. Forsythe, A. Oral presentation presented at the European Society for Medical Oncology Congress (ESMO), Munich, October 21, 2018.
- Economic Burden of Acute Steroid-Refractory Graft Versus Host Disease in Commercially Insured Pediatric Patients. Grabner, M., E. Strati, K. Sandman, and A. Forsythe. Journal of Managed Care & Specialty Pharmacy 26, no. 4-a (April 2020). https://doi.org/10.18553/jmcp.2020.26.4-a.s1.
- Economic Burden of Acute Steroid-Refractory Graft Versus Host Disease in Commercially Insured Pediatric Patients. Grabner, M., E. Strati, K. Sandman, and A. Forsythe. Presented at the AMCP (Virtual), Houston, Texas, April 21, 2020.
- Younger Patients Are Impacted By Post-Transplant Lymphoproliferative Disorder: Findings from a Systematic Literature Review of Real-World Evidence. Watson, C., H. Xu, A. Forsythe, S. A. Garib, and A. Barlev. Blood 132, no. Supplement 1 (November 29, 2018): 5841–5841. https://doi.org/10.1182/blood-2018-99-113622.
- Real World Evidence on the Burden of Illness Experienced by Patients With Systemic Mycoses, Forsythe, A., J. Hearnden, G. Lewis, and R. Schreiber. 1, 2018.
- Real World Evidence On The Burden Of Illness Experienced By Patients With Hematological Malignancies And Systemic Mycoses. Forsythe, A., J. Hearnden, G. Lewis, and R. Schreiber. Stockholm, Sweden, 2018. https://library.ehaweb.org/eha/2018/stockholm/214741/anna.forsythe.real.world.evidence.on.the.burden.of.illness.experienced.by.html?f=menu%3D14%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Aspeaker%3D619413.
- Real World Evidence on the Burden of Illness Experienced by HIV Patients with Systemic Mycoses, Schreiber, R., A. Forsythe, J. Hearnden, and G. Lewis. 2018. https://academic.oup.com/mmy/article/56/suppl_2/S1/5033473.
- US Database Study: Burden and Healthcare Resource Utilization in Adults with Systemic Endemic Mycoses and Aspergillosis. Forsythe, Anna, Gareth Lewis, Robyn Jordan, and George R Thompson. Journal of Comparative Effectiveness Research, April 22, 2020, cer-2020-0019. https://doi.org/10.2217/cer-2020-0019.
- Benefit-Risk Comparison in Patients with Immune Thrombocytopenia (ITP) Receiving Eltrombopag or Romiplostim: Real World Evidence (RWE) from 26 Hospital Institutions. Forsythe, A., A. Roy, M. Bhor, A. Allepuz, M. D. S. O. Portella, C. Kwon, and G. Tremblay. Atlanta, GA, USA, 2017. https://ashpublications.org/blood/article/130/Supplement 1/3409/114492/Benefit-Risk-Comparison-in-Patients-with-Immune.
- Bleeding-Related Episodes (BRE) in Patients With Immune Thrombocytopenia (ITP) Receiving Eltrombopag (EPAG) or Romiplostim (ROMI): Real World Evidence from 26 US Institutions. Forsythe, A, A Roy, M Bhor, and M Socorro O Portella. Glasgow, Scotland, 2017. https://doi.org/10.1016/j.jval.2017.08.834.
- Economic Burden of Immune Thrombocytopenia (ITP) In Patients Receiving Eltrombopag (EPAG) And Romiplostim (ROMI): Real World Evidence From 26 US Institutions. Forsythe, A, M Bhor, A Roy, M Socorro O Portella, C Kwon, and G Tremblay. Glasgow, Scotland, 2017. https://doi.org/10.1016/j.jval.2017.08.870.
- Health Care Resource Use (HCRU) Due To Bleeding Related Episodes (BRE) In Patients With Immune Thrombocytopenic Purpura (ITP) Receiving Eltrombopag (EPAG), Romiplostim (ROMI), Or Rituximab (RITUX): Real World Evidence (RWE) From 27 US Institutions. Kwon, C., A. Forsythe, A. Roy, M. Bhor, M. D. S. O. Portella, and G. Tremblay. Glasgow, Scotland, 2017. https://doi.org/10.1016/j.jval.2017.08.903.
- Real-World Evidence on Clinical Outcomes in Immune Thrombocytopenia Treated with Thrombopoietin Receptor Agonists. Forsythe, Anna, John Schneider, Timothy Pham, Menaka Bhor, Qayyim Said, Alejandro Allepuz, Maria do Socorro O Portella, Christina S Kwon, and Anuja Nidumolu Roy. Journal of Comparative Effectiveness Research, March 16, 2020, cer-2019-0177. https://doi.org/10.2217/cer-2019-0177.
- Understanding the Burden of Idiopathic Generalized Epilepsy in the United States, Europe, and Brazil: An Analysis from the National Health and Wellness Survey. Gupta, S., P. Kwan, E. Faught, W. Tsong, A. Forsythe, and P. Ryvlin. Epilepsy & Behavio : E&B 55 (February 2016): 146–56. https://doi.org/10.1016/j.yebeh.2015.12.018.
- Treatment Patterns and Health Care Resources Use (HCRU) in Patients with Acute Myeloid Leukemia (AML): Real World Evidence (RWE) from 30 US Institutions. Kwon, C., P. Brandt, S. Manson, A. Fuentes-Alburo, and A. Forsythe. Blood 130, no. Supplement 1 (December 7, 2017): 5655–5655. https://doi.org/10.1182/blood.V130.Suppl_1.5655.5655.
- An SLR of Clinical and Real-World Evidence in Relapsed/Refractory Multiple Myeloma (RRMM) Studies to Inform Clinical Decision-Making in the US. Forsythe, A., D. Tomaras, K. Parikh, and R. Copher. Boston, MA, USA, 2019. https://linkinghub.elsevier.com/retrieve/pii/S2152265019318324.
- Comparative Effectiveness of Treatments In Epidermal Growth Factor Receptor Mutant (EGFR-MUTANT) Non-Small Cell Lung Cancer (NSCLC) Patients WHO Failed On Prior Targeted Therapies: A Systematic Literature Review (SLR). Shor, A., A. Forsythe, S. Li, and A. Galaznik. Baltimore, MD, USA, 2018. https://doi.org/10.1016/j.jval.2018.04.096.
- Clinical and Real-world Outcomes in Patients With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions in Non-small Cell Lung Cancer (NSCLC): a Meta-analysis. Dimitrios Tomaras , Huamao M Lin, Anna Forsythe, Victoria Crossland, Sai-Hong Ou. Virtual ESMO, 2020.
- Epidemiological, Clinical and Humanistic Burden Among ALK+ Non-Small Cell Lung Cancer (ALK+NSCLC) Patients Treated With First-Line ALK Inhibitors: Results Of A Systematic Literature Review (SLR). Pan, X., C. S. Kwon, S. A. Garib, A. Forsythe, and H. M. Lin. New Orleans, LA, USA, 2019. https://doi.org/10.1016/j.jval.2019.04.127.
- Burden Of Brain Metastases (BM) In ALK+ Non-Small Cell Lung Cancer (ALK+ NSCLC) Treated With First-Line ALK Inhibitors: Results Of A Systematic Literature Review (SLR). Pan, X., C. S. Kwon, S. A. Garib, A. Forsythe, and H. M. Lin. Copenhagen, Denmark, 2019. https://doi.org/10.1016/j.jval.2019.09.219.
- Comparative Effectiveness of Induction Treatment Regimens in NDMM: Results of an SLR to Inform Clinical Decision-Making in the US. Forsythe, A., E. Kim, K. Parikh, and R. Copher. Boston, MA, USA, 2019. https://linkinghub.elsevier.com/retrieve/pii/S2152265019317276.
- Effectiveness of Maintenance Treatment in Newly Diagnosed Multiple Myeloma (NDMM): Results of an SLR to Inform Clinical Decision-Making in the US. Forsythe, A., E. Kim, K. Parikh, and R. Copher. Boston, MA, USA, 2019. https://linkinghub.elsevier.com/retrieve/pii/S2152265019318749.
- Systematic Literature Review (SLR) of Evidence on the Humanistic Burden of Relapsed/Refractory Multiple
Myeloma (RRMM). Forsythe A, Kwon CS, Kim ME et al. Value in Health (2020) – Accepted for poster presentation at ISPOR EU 2020. - A Systematic Literature Review (SLR) of Health State Utility Values (HSUVS) in Relapsed/Refractory Multiple Myeloma (RRMM). Forsythe A, Kim ME, Kwon CS et al. Value in Health (2020) – Accepted for poster presentation at ISPOR EU 2020.
- The Economic And Humanistic Burden Of Graft-Versus-Host Disease (GVHD) In Pediatric Patients: A Systematic Literature Review (SLR). Tomaras, D., E. Strati, and A. Forsythe. Amsterdam, UK, 2019. http://journals.lww.com/10.1097/01.HS9.0000561156.61407.1f.
- Allogeneic Hematopoietic Stem Cell Transplantations (ALLO-HSCT) Are Associated With Poor Quality Of Life (QOL) And Economic Burden Due To Graft-Versus-Host Disease (GVHD) Complications: Results Of A Systematic Literature Review (SLR). Tomaras, D., M. Dolph, P. Caudrelier, M. Dumont-Lagacé, and A. Forsythe. In Value in Health. New Orleans, LA, USA, 2019. https://doi.org/10.1016/j.jval.2019.04.409.
- Acute Graft Versus Host Disease (GVHD), Chronic GVHD And Non-Relapse Mortality (NRM) Associated With Mismatched Allogeneic Hematopoietic Stem Cell Transplantation (ALLO-HSCT): A Systematic Review. Tomaras, D., M. Dolph, P. Caudrelier, M. Dumont-Lagacé, and A. Forsythe. New Orleans, LA, USA, 2019. https://doi.org/10.1016/j.jval.2019.04.410.
- Comparative Effectiveness Of Allogeneic Hematopoietic Stem Cell Transplantations (ALLO-HSCT) From Different Graft Sources In Acute Myeloid Leukemia (AML): Results Of A Systematic Literature Review. Tomaras, D., M. Dolph, P. Caudrelier, M. Dumont-Lagacé, and A. Forsythe. New Orleans, LA, USA, 2019. https://doi.org/10.1016/j.jval.2019.04.150.
- Treatment Patterns for Patients with Post-Transplant Lymphoproliferative Disorder Who Fail Rituximab after Allogeneic Hematopoietic Stem Cell Transplantation: Findings from a Systematic Literature Review. Xu, H., C. Watson, S. A. Garib, A. Forsythe, and A. Barlev. San Diego, CA, 2018. https://ashpublications.org/blood/article/132/Supplement 1/4777/262154/Treatment-Patterns-for-Patients-with-Post.
- A Systematic Literature Review of Real-World Evidence in Post-Transplant Lymphoproliferative Disorder. Xu, H., A. Forsythe, A. Barlev, N. Rashid, and C. Watson. Blood 132, no. Supplement 1 (November 29, 2018): 5839–5839. https://doi.org/10.1182/blood-2018-99-113583.
- Patient-Focused Benefits Of At-Home Vs In-Clinic Administration Of Cancer Therapy. Sandman K, Bell T. Value in Health (2020).
- The Humanistic And Economic Burden Of Myasthenia Gravis (MG) - A Debilitating & Costly Disease. Tomaras D, Marshall S, Forsythe A. Value in Health (2020).
- Symptoms, Delayed Diagnosis And Quality Of Life (QOL) Deterioration - Exploring The Burden Of Amyotrophic Lateral Sclerosis (ALS). Forsythe A, Vieweg DC, Marshall S, Tomaras D, Kim E. Value in Health (2020).
- Amyotrophic Lateral Sclerosis (ALS) Results In High Direct And Indirect Costs To Patients, Caregivers, And Healthcare Systems. Forsythe A, Kim ME, Tomaras D, Kielhorn A. Value in Health (2020).
- Use Of Computer-Assisted Methods To Realize The Concept Of A Living Systematic Review Via An Online Platform. Hearnden, J., K. Dudoit, E. Kim, G. Tremblay, and A. Forsythe. Copenhagen, Denmark, 2019. https://doi.org/10.1016/j.jval.2019.09.1736.
- Clinical And Humanistic Burden Among Non-Muscle Invasive Bladder Cancer Patients: Results Of A Systematic Literature Review. Kwon, C. S., L. J. Lee, A. Forsythe, and C. Mamolo. Copenhagen, Denmark, 2019. https://doi.org/10.1016/j.jval.2019.09.231.
- Systemic Therapy in Second-Line Metastatic Triple Negative Breast Cancer (MTNBC): A Systematic Literature Review (SLR) and Meta-Analysis (MA) of Efficacy. Kaufman, P. A., C. S. Kwon, J. Feliciano, T. Westley, A. Forsythe, P. Garfin, and L. Brown. Barcelona, Spain, 2019.
- An evaluation of the efficacy and safety of second line (2L) treatments in metastatic colorectal cancer (mCRC). Hitron, M., Smith, G., Forsythe, A., Harricharan, S., Shah, MA. Journal of Managed Care & Specialty Pharmacy (2020) – Accepted for presentation at AMCP Nexus in October 2020.
- Challenges of Descriptive Epidemiology in Rare Diseases: A Systematic Literature Review (SLR) and Meta-Analysis (MA) of Solid Tumors with Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusions. Forsythe A, Zhang WW, Strauss UP, Fellous M, Korei M, Keating KN. Value in Health (2020) – Accepted for poster presentation at ISPOR EU 2020.
- Unmet Needs & Burden of Recurrent Pericarditis (RP): Results of A Systematic Literature Review (SLR). Crotty, C., A. Forsythe, and M. Magestro. New Orleans, LA, USA, 2019. https://doi.org/10.1016/j.jval.2019.04.445.
- Real-Time Systematic Literature Reviews (SLR) - Dream or Reality With Computer-Assisted Methods: A Case Study In Acute Myeloid Leukemia (AML). Forsythe, A., J. Hearnden, K. Dudoit, C. Crotty, and G. Tremblay. New Orleans, LA, USA, 2019. https://doi.org/10.1016/j.jval.2019.04.364.
- Understanding the Clinical Burden of Acute Respiratory Distress Syndrome (ARDS) in a Covid-19 Era: a Targeted Search and Epidemiological Model. Tomaras D , Harricharan S , Tremblay G , Forsythe A. Value in Health (2020) – Accepted for poster presentation at ISPOR EU 2020.
- Patterns of Undertreatment Among Patients with Acute Myeloid Leukemia (AML) Not Receiving Standard Intensive Induction Chemotherapy. Hubscher, E. Sikirica, S. Bell, TJ. et al.; Blood 2020; 136 (Supplement 1): 18–19. doi: https://doi.org/10.1182/blood-2020-137425
- Conceptual Framework For Economic Evaluation Of Knee Kinesiography For The Management Of Knee Osteoarthritis. Azimpour K, Tremblay G, Hagemeister N, Cagnin A, Fuentes A. Value in Health (2020).
- Economic Value Drivers In Severe Red Blood Cell Disorders: A Review And Development Of An Economic Conceptual Framework. Tremblay G, Lemay W. Value in Health (2020).
- Economic Evaluation of Severe Anaemia: Review-Based Recommendations and a Conceptual Framework. Tomaras, D., W. Lemay, and G. Tremblay. European Medical Journal 5, no. 3 (September 17, 2020): 45–54. https://doi.org/10.33590/emj/20-00102.
- A Conceptual Framework For Economic Evaluation Of Beta-Thalassemia. Tremblay G, Tomaras D, Mearns ES, Copher R. Value in Health (2020).
- The Role Of Early Value Framework In A Successful Reimbursement Journey. Tomaras, D., L. Ramjee, A. Forsythe, and G. Tremblay. Copenhagen, Denmark, 2019. https://doi.org/10.1016/j.jval.2019.09.2177.
- A Decision Framework for Treating Chronic Immune Thrombocytopenia with Thrombopoietin Receptor Agonists. Dolph, M., A. Roy, M. Bhor, J. Hearnden, C. S. Kwon, A. Forsythe, G. Tremblay, and A. Briggs. Journal of Comparative Effectiveness Research 7, no. 8 (August 2018): 775–84. https://doi.org/10.2217/cer-2018-0034.
- Using Cure Models In Economic Analyses: A Review And Conceptual Guideline. Dolph M, Tremblay G. Value in Health (2020).
- Clinical and Key Opinion Leaders Validation In Health Economics Model And Comparative Effectiveness: A Guide For Non-Expert Audience. Azimpour, K., G. Tremblay, and A. Forsythe. Copenhagen, Denmark, 2019. https://doi.org/10.1016/j.jval.2019.09.2197.
- What Is A Good or Bad Number Need to Treat (NNT) Value? A Literature Review. Azimpour, K., G. Tremblay, and A. Forsythe. Copenhagen, Denmark, 2019. https://doi.org/10.1016/j.jval.2019.09.1623.
- Per-Member Per-Month (PMPM) Expenditure Value in Oncology: A Quick Literature Review And Opinion. Tremblay, G., K. Azimpour, and A. Forsythe. Copenhagen, Denmark, 2019. https://doi.org/10.1016/j.jval.2019.09.2198.
- Incremental Quality-Adjusted Survival Analysis When No Head To Head Data Are Available: A Case Study Of Midostaurin (MIDO) Versus Standard Of Care (SOC) In Patients With Advanced Systemic Mastocytosis (ASM). Cariou, C., G. Tremblay, M. Dolph, P. S. Brandt, and A. Forsythe. Barcelona, Spain, 2018. https://doi.org/10.1016/j.jval.2018.09.2791.
- A Criterion-Based Approach to Systematic and Transparent Comparative Effectiveness: A Case Study in Psoriatic Arthritis. Tremblay, G., T. Westley, A. Forsythe, C. Pelletier, and A. Briggs. Journal of Comparative Effectiveness Research 8, no. 15 (November 2019): 1265–98. https://doi.org/10.2217/cer-2019-0064.
- A Criterion-Based Approach to Systematic and Transparent Comparative Effectiveness Research: A Case Study in Psoriatic Arthritis. Tremblay, G., A. Forsythe, C. Pelletier, and A. Briggs. Dallas, TX, 2017. https://www.jmcp.org/doi/10.18553/jmcp.2017.23.10-a.s1.
- Determination of the Most Appropriate Method for Extrapolating Overall Survival Data from a Placebo-Controlled Clinical Trial of Lenvatinib for Progressive, Radioiodine-Refractory Differentiated Thyroid Cancer. Tremblay, G., C. Livings, L. Crowe, V. Kapetanakis, and A. Briggs. ClinicoEconomics and Outcomes Research Volume 8 (June 2016): 323–33. https://doi.org/10.2147/CEOR.S107498.
- Covariate-Adjusted Analysis of the Phase 3 REFLECT Study of Lenvatinib versus Sorafenib in the Treatment of Unresectable Hepatocellular Carcinoma. Briggs, Andrew, Bruno Daniele, Katherine Dick, Thomas R. Jeffry Evans, Peter R. Galle, Richard A. Hubner, Carlos Lopez, Uwe Siebert, and Gabriel Tremblay. British Journal of Cancer, April 8, 2020, 1–6. https://doi.org/10.1038/s41416-020-0817-7.
- Is Progression-Free Survival a More Relevant Endpoint than Overall Survival in First-Line HR+/HER2- Metastatic Breast Cancer? Forsythe, A., D. Chandiwana, J. Barth, M. Thabane, J. Baeck, A. Shor, and G. Tremblay. Cancer Management and Research 10 (2018): 1015–25. https://doi.org/10.2147/CMAR.S162714.
- Progression-Free Survival/Time to Progression as a Potential Surrogate for Overall Survival in HR+, HER2- Metastatic Breast Cancer. Forsythe, A., D. Chandiwana, J. Barth, M. Thabane, J. Baeck, and G. Tremblay. Breast Cancer (Dove Medical Press) 10 (2018): 69–78. https://doi.org/10.2147/BCTT.S162841.
- PFS/TTP as a Potential Surrogate for OS in HR+, HER2– MBC. Forsythe, A., D. Chandiwana, J. Barth, M. Thabane, J. Baeck, A. Shor, and G. Tremblay. Madrid, Spain, 2017.
- Is PFS a More Relevant Endpoint than OS in 1L HR+, HER2– MBC? A Systematic Literature Review. Forsythe, A., D. Chandiwana, J. Barth, M. Thabane, J. Baeck, A. Shor, and G. Tremblay. Madrid, Spain, 2017.
- Application of Oncology Value Frameworks to the 2nd Line Treatments in Renal Cell Carcinoma (2L-RCC). Forsythe, A., J. Schneider, A. Shor, P. Patel, and A. Briggs. Boston, MA, USA, 2017. https://doi.org/10.1016/j.jval.2017.05.005.
- Defining the Value: Do the New Oncology Frameworks in the Us Aim at Objective Valuation? – A Case Study in Multiple Myeloma. Forsythe, A., and E. Pezalla. Oral Presentation presented at the 2nd Annual Pharma Pricing, Reimbursement and Marketing Access 2016, London, England, June 8, 2016.
- Health Technology Assessment (HTA) Review Of Cell & Gene Therapies: The Road To Reimbursement. Vu BK, Forsythe A, Nguyen K, Tomaras D. Value in Health (2020).
- Global Oncology Access - The Relative Difficulty Of Reimbursement Across Four Health technology Assessment (HTA) Agencies. Nguyen K, Forsythe A, Azimpour K, Vu BK, Tomaras D. Value in Health (2020).
- From Regulatory Approval to Reimbursement of Car-Ts: Can Real World Evidence Help Close The Data Gap? Forsythe, A. Oral Presentation presented at the 1st European CAR T Cell Meeting of the European Heamatology Association, Paris, France, February 15, 2019.
- Always up-to-Date Systematic Literature Reviews (SLRS Now a Reality - an Example in NEWLY Diagnosed Acute Myeloid Leukemia (ND AML) and Relapsed/Refractory Acute Lymphoblastic Leukemia (RR ALL). Richard ME , Harricharan S , Forsythe A. Value in Health (2020) – Accepted for poster presentation at ISPOR EU 2020.
Contact Us
Fill in the form below to get in touch